Cathay Biotech (SH:688065) Xin Lang Cai Jing·2025-09-08 05:35Group 1 - The core viewpoint of the news is that Kaisa Bio has seen a stock price increase of 5.1%, reaching 54.77 CNY per share, with a trading volume of 257 million CNY and a turnover rate of 0.82%, resulting in a total market capitalization of 39.505 billion CNY [1] - Kaisa Bio, established on November 24, 2000, and listed on August 12, 2020, focuses on the research, production, and sales of new bio-based materials using synthetic biology and biomanufacturing technologies [1] - The company's main revenue sources are long-chain dicarboxylic acids (89.98%), other products (6.08%), and bio-based polyamides (3.95%) [1] Group 2 - Among Kaisa Bio's top ten circulating shareholders, Huaxia Fund's ETF (588000) increased its holdings by 3.4%, amounting to 19.8524 million shares, with an estimated floating profit of approximately 52.8074 million CNY [2] - The Huaxia ETF was established on September 28, 2020, with a current scale of 83.343 billion CNY, achieving a year-to-date return of 27.97% and a one-year return of 89.57% [2] - The fund manager, Rong Ying, has a tenure of 9 years and 310 days, with a total asset scale of 138.288 billion CNY, while Zhao Zongting has a tenure of 8 years and 147 days, managing 389.148 billion CNY [3]